@article{negrier:hal-02552562,
TITLE = {Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial},
AUTHOR = {N{\'e}grier, Sylvie and Rioux-Leclercq, Nathalie and Ferlay, C{\'e}line and Gross-Goupil, Marine and Gravis, Gw{\'e}naelle and Geoffrois, Lionel and Chevreau, Christine and Boyle, Helen and Rolland, Fr{\'e}d{\'e}ric and Blanc, Ellen and Ravaud, Alain and Dermeche, Slimane and Fl{\'e}chon, Aude and Albiges, Laurence and P{\'e}rol, David and Escudier, Bernard},
URL = {https://univ-lyon1.hal.science/hal-02552562},
JOURNAL = {European Journal of Cancer},
PUBLISHER = {Elsevier},
VOLUME = {129},
PAGES = {107 - 116},
YEAR = {2020},
MONTH = Apr, DOI = {10.1016/j.ejca.2020.02.001},
KEYWORDS = {Tyrosine kinase ; Advanced renal cancer ; Papillary renal cell carcinoma ; VEGF inhibitor ; Vascular endothelial growth factor},
PDF = {https://univ-lyon1.hal.science/hal-02552562/file/AXIPAP%20VF%20EJC%20HAL%20UCBL.pdf},
HAL_ID = {hal-02552562},
HAL_VERSION = {v1},
}